Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Corneal Neovascularization: early-phase trial registry
1 of 4 indexed Corneal Neovascularization trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Corneal Neovascularization: 4 US clinical trials tracked, 1 recruiting.
Corneal Neovascularization is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Reza Dana, MD, running 1 of these trials.
Enrollment posture brief
Registry condition corneal-neovascularization
OPEN 1 | RECR 25% | LATE 0 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Corneal Neovascularization lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Corneal Neovascularization on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Corneal Neovascularization is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Corneal Crosslinking for Treatment of Corneal Neovascularization
Price Vision Group
NCT04787471
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
Medical College of Hampton Roads
NCT00004430
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
Reza Dana, MD
NCT01072357
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
University of Miami
NCT00769145
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Corneal Neovascularization records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Corneal Neovascularization trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Corneal Neovascularization page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Corneal Neovascularization trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Reza Dana, MD sponsors the most Corneal Neovascularization trials on record, review their full trial history before evaluating a specific study. See Reza Dana, MD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Corneal Neovascularization condition card totals 4 registered trials; most-linked intervention 0.9% NaCl & Refresh Liquigel; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.